Brief: Mereo Biopharma Announces Positive Top-Line Efficacy And Safety Data From “Astraeus” Phase 2 Trial Of Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Emphysema
09/05/2022 12:23
May 9 (Reuters) - Mereo Biopharma Group PLC MAH0y.F :
* MEREO BIOPHARMA ANNOUNCES POSITIVE TOP-LINE EFFICACY AND
SAFETY
DATA FROM “ASTRAEUS” PHASE 2 TRIAL OF ALVELESTAT IN ALPHA-1
ANTITRYPSIN DEFICIENCY-ASSOCIATED EMPHYSEMA
* MEREO BIOPHARMA GROUP- AT HIGH DOSE, ALVELESTAT
DEMONSTRATED
STATISTICALLY SIGNIFICANT CHANGES VERSUS PLACEBO IN ALL 3
PRIMARY BIOMARKER ENDPOINTS
Source text for Eikon: ID:nGNXc1KFNJ
Further company coverage: MAH0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mereo BioPharma
See all newsBrief: Sentynl Therapeutics And Mereo Biopharma Announce Option And License Agreement For Alvelestat In Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Brief: Mereo BioPharma Q2 Operating Income USD -7.03 Million
Brief: Mereo BioPharma Q1 Net Income USD -6.719 Million
Brief: Mereo BioPharma FY Revenue USD 500 Thousand Vs. IBES Estimate USD 520 Thousand